Open Orphan is a rapidly growing niche CRO pharmaceutical services group which is the world leader in infectious and respiratory diseases through the use of human challenge clinical trials.
Open Orphan PLC said Wednesday that its hVIVO subsidiary has signed a 7.3 million pounds ($9.1 million) influenza human challenge study contract with an...
Open Orphan plc., announces that hVIVO, a subsidiary of Open Orphan, has signed a £5m respiratory syncytial virus (RSV) human challenge study contract with...